Because TDP-43 plays a central role in the pathogenesis of ALS/FTD, our TDP-43-targeting approach has great potential for treating most patients with ALS/FTD as well as those with other TDP-43 proteinopathies. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.